ACCENDRA HEALTH INC/VA/ — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Kenneth Gardner-Smith, a Board member since March 2022, was named President and CEO effective early Q4 2026, succeeding retiring Edward Pesicka. Gardner-Smith's compensation includes: $1M annual base salary, 130% AIP target ($1.3M), $6M annual LTI grant (25% RSUs, 75% PSUs), $650K sign-on bonus (repayable if resigned within 24 months), and $2M inducement grant in cash-settled SARs with 20x maximum payout ($40M theoretical). Scott Lloyd also appointed Chief Commercial Officer effective October 5, 2026.
Why this rating
CEO succession with internal board candidate mitigates risk; total first-year comp ~$9.65M is ~1.4% of $677.5M market cap—meaningful but not transformational. Leadership continuity planned; no operational disruption flagged.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.